Management of Hypertriglyceridemia

First-Line Treatment Approach

Lifestyle modifications, including weight loss, increased physical activity, smoking cessation, reduced alcohol intake, and dietary changes, remain the foundation of hypertriglyceridemia management, as recommended by the American College of Cardiology 1, 2
For patients with moderate hypertriglyceridemia and elevated cardiovascular risk, statins are recommended as first-line pharmacological therapy, according to the American College of Cardiology 1, 3
For severe hypertriglyceridemia, fibrates are recommended as first-line therapy to reduce pancreatitis risk, as suggested by the American Academy of Family Physicians 4 and the American Diabetes Association 5

High-potency statins, such as rosuvastatin and atorvastatin, are effective for triglyceride reduction in patients with combined hyperlipidemia, as stated by the American College of Cardiology 1 and the American Diabetes Association 5
For patients with baseline triglycerides >250 mg/dL, high-potency statins provide significant triglyceride reductions, according to the American College of Cardiology 1

The triglyceride-lowering effect of statins correlates with baseline triglyceride levels, with minimal effect when baseline is <150 mg/dL, but substantial when >250 mg/dL, as noted by the American Diabetes Association 5
For patients with combined hyperlipidemia, high-potency statins are particularly beneficial, as recommended by the American College of Cardiology 1 and the American Diabetes Association 5
In patients with severe hypertriglyceridemia, statins alone are not recommended as primary therapy, but may be used as part of combination therapy, as suggested by the American Academy of Family Physicians 4 and the American College of Cardiology 1

For triglycerides 150-500 mg/dL with elevated cardiovascular risk, the American College of Cardiology recommends starting with a high-potency statin, such as rosuvastatin or atorvastatin 1, 3
For triglycerides ≥500 mg/dL, the American Academy of Family Physicians suggests starting with a fibrate, such as gemfibrozil or fenofibrate, and considering adding a high-potency statin if LDL-C is also elevated 4, 6

The American College of Cardiology recommends monitoring liver function tests, creatine kinase, glucose, and creatinine before starting statin therapy, and periodically checking liver enzymes, especially in patients with risk factors for hepatotoxicity 7
The American College of Cardiology also suggests measuring creatine kinase if muscle symptoms develop, and monitoring glycemic control in patients with diabetes or at risk for diabetes 7

The American College of Cardiology notes that statin-fibrate combinations increase the risk of myopathy, and should be used with caution and monitored closely 6, 5
The American Academy of Family Physicians and the American College of Cardiology agree that statins alone are insufficient for severe hypertriglyceridemia, where pancreatitis risk is the primary concern 4, 1